Press Releases - Navitor Pharmaceuticals, Inc.

Warning: Undefined variable $last_post_year in /data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php on line 131

Warning: Undefined variable $last_post_year in /data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php on line 132

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2024

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2022

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2020

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2019

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2018

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2017

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2016

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2015

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

Warning

/data/20/3/28/49/3517864/user/3917933/htdocs/wp-content/themes/navitor/page-templates/press.php

170

2014

Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.

February 2, 2022

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

April 21, 2020

Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression

September 12, 2019

Navitor Expands Leadership Team with Appointment of James Randall Owen, M.D. as Chief Medical Officer

July 15, 2019

Navitor Pharmaceuticals Announces Peer-Reviewed Publication in Journal of Clinical Investigation Highlighting Rapid Antidepressant Effects of NV-5138

April 16, 2019

Navitor Pharmaceuticals Announces Peer-Reviewed Publication Detailing the Discovery and Development of NV-5138

March 11, 2019

Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, A Novel mTORC1 Activator in Patients with Treatment-Resistant Depression

January 24, 2019

Navitor Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

November 20, 2018

Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer

August 2, 2018

Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression

June 26, 2018

Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference

May 17, 2018

Navitor Pharmaceuticals to Present at Cowen and Company Healthcare Conference

March 7, 2018

Scientific Poster: Sestrin2 modulator NV-5138, shows ketamine-like rapid antidepressant effects via direct activation of mTORC1 signaling

November 15, 2017

Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017

November 15, 2017

Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity

November 9, 2017

No Press Releases in 2016

January 1, 2016

Navitor Pharmaceuticals Announces $33 Million Series B Financing

December 18, 2015

Navitor Pharmaceuticals’ Scientific Founder Makes Landmark Discovery of the Molecular Sensor for the Amino Acid Leucine

October 8, 2015

Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board

September 1, 2015

Navitor Pharmaceuticals Appoints Paul Friedman, MD, to Its Board of Directors

June 15, 2015

Navitor Pharmaceuticals Selected as “Hottest Startup” in Healthcare at New England Venture Capital Association’s 2015 NEVY Awards

May 14, 2015

Navitor Pharmaceuticals Appoints Eddine Saiah, PhD, as Vice President of Drug Discovery

November 20, 2014

FierceBiotech names Navitor Pharmaceuticals as one of its “Fierce 15” Biotech Companies of 2014

September 22, 2014

Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing for Novel Drug Discovery Targeting Cellular Nutrient Signaling to Treat Chronic Diseases and Rare Disorders

June 19, 2014

News

Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression

Navitor Expands Leadership Team with Appointment of James Randall Owen, M.D. as Chief Medical Officer

Navitor Pharmaceuticals Announces Peer-Reviewed Publication in Journal of Clinical Investigation Highlighting Rapid Antidepressant Effects of NV-5138

Navitor Pharmaceuticals Announces Peer-Reviewed Publication Detailing the Discovery and Development of NV-5138

Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, A Novel mTORC1 Activator in Patients with Treatment-Resistant Depression

Navitor Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer

Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression

Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference

Navitor Pharmaceuticals to Present at Cowen and Company Healthcare Conference

Scientific Poster: Sestrin2 modulator NV-5138, shows ketamine-like rapid antidepressant effects via direct activation of mTORC1 signaling

Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017

Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity

No Press Releases in 2016

Navitor Pharmaceuticals Announces $33 Million Series B Financing

Navitor Pharmaceuticals’ Scientific Founder Makes Landmark Discovery of the Molecular Sensor for the Amino Acid Leucine

Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board

Navitor Pharmaceuticals Appoints Paul Friedman, MD, to Its Board of Directors

Navitor Pharmaceuticals Selected as “Hottest Startup” in Healthcare at New England Venture Capital Association’s 2015 NEVY Awards

Navitor Pharmaceuticals Appoints Eddine Saiah, PhD, as Vice President of Drug Discovery

FierceBiotech names Navitor Pharmaceuticals as one of its “Fierce 15” Biotech Companies of 2014

Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing for Novel Drug Discovery Targeting Cellular Nutrient Signaling to Treat Chronic Diseases and Rare Disorders